Sakurai Hiroaki, Nishi Akito, Sato Naoya, Mizukami Junko, Miyoshi Hidetaka, Sugita Takahisa
Discovery Research Laboratory, Tanabe Seiyaku Co., Ltd., 16-89 Kashima 3-chome, Yodogawa-ku, 532-8505, Osaka, Japan.
Biochem Biophys Res Commun. 2002 Oct 11;297(5):1277-81. doi: 10.1016/s0006-291x(02)02379-3.
TAK1 mitogen-activated protein kinase kinase kinase (MAP3K) is activated by its specific activator, TAK1-binding protein 1 (TAB1). A constitutively active TAK1 mutant has not yet been generated due to the indispensable requirement of TAB1 for TAK1 kinase activity. In this study, we generated a novel constitutively active TAK1 by fusing its kinase domain to the minimal TAK1-activation domain of TAB1. Co-immunoprecipitation assay demonstrated that these domains interacted intra-molecularly. The TAK1-TAB1 fusion protein showed a significant MAP3K activity in vitro and activated c-Jun N-terminal kinase/p38 MAPKs and IkappaB kinase in vivo, which was followed by increased production of interleukin-6. These results indicate that the fusion protein is useful for characterizing the physiological roles of the TAK1-TAB1 complex.
转化生长因子β激活激酶1(TAK1),即丝裂原活化蛋白激酶激酶激酶(MAP3K),由其特异性激活剂TAK1结合蛋白1(TAB1)激活。由于TAB1对TAK1激酶活性不可或缺,因此尚未产生组成型活性TAK1突变体。在本研究中,我们通过将TAK1的激酶结构域与TAB1的最小TAK1激活结构域融合,生成了一种新型的组成型活性TAK1。免疫共沉淀试验表明,这些结构域在分子内相互作用。TAK1-TAB1融合蛋白在体外表现出显著的MAP3K活性,并在体内激活c-Jun氨基末端激酶/p38丝裂原活化蛋白激酶和IκB激酶,随后白细胞介素-6的产生增加。这些结果表明,该融合蛋白有助于表征TAK1-TAB1复合物的生理作用。